

NanoSpeed Diagnostics – Pioneering Rapid Testing for Better Health

NanoSpeed Diagnostics Inc., founded in 2009 and headquartered in Edmonton, is a leading force in point-of-care diagnostics. Using proprietary lateral flow immunoassay (LFIA) platforms, the company develops cost-effective, reliable test kits for health screening. In 2022, NanoSpeed expanded into an 11,000 sq ft manufacturing facility and secured ISO 13485 / MDSAP certification, reinforcing its commitment to regulatory compliance and quality standards.

Test4D Rapid Vitamin D Test:

One of NanoSpeed's flagship innovations is Test4D, a platform for measuring vitamin D levels at the point of care. It is considered the world's first rapid vitamin D test, enabling clinicians and users to gain near-instant insights without requiring centralized labs. In April 2025, Test4D Serum received approval from Health Canada, marking a significant regulatory milestone and enabling broader adoption in Canadian clinical settings.

How It Works & Technical Highlights:

The user dispenses a small volume of blood (via finger prick) into the cassette, adds buffer drops, and waits approximately 10 minutes before reading results. NanoSpeed's technology integrates a cube reader system, which digitally reads the cassette's test and control lines to interpret results reliably and reduce human error.

The cube reader detects invalid runs ('FAIL', 'ERR') or expired tests, ensuring output quality. Validation tests report a 94% correlation with gold-standard LC/MS reference methods, demonstrating strong analytical performance.

Advantages & Impact on Preventive Health:

- **Speed and Convenience:** Results available in minutes rather than days.
- **Accessibility:** Portable diagnostic solutions allow healthcare delivery even in underserved regions.
- **Empowerment:** Easy testing encourages proactive health monitoring.
- **Accuracy:** Cube reader digital interpretation reduces human error.

Use Cases & Adoption Channels:

NanoSpeed's technology is used across clinics, pharmacies, mobile health units, and

diagnostic labs. It supports preventive care, chronic disease management, and bone health assessment for orthopedic and dental applications.

Challenges & Considerations:

Regulatory approvals like Health Canada's are essential for trust and expansion. Proper user training, quality assurance, and evidence-based adoption drive clinical confidence. Ensuring reliable production and distribution is crucial for global scale-up.

A Vision for the Future:

NanoSpeed is positioned at the intersection of diagnostics, consumer health, and digital medicine. As point-of-care testing grows, the platform could expand to other analytes beyond vitamin D. Integration with telemedicine and mobile health tools will further enhance accessibility and impact.

Author / Publisher: NanoSpeed Diagnostics Inc.

Official Website: <https://nanospeed.ca/>